---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-012263"
form_type: "8-K"
ticker: "CSTL"
cik: "0001447362"
company_name: "CASTLE BIOSCIENCES INC"
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:31:47.036331+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Castle Biosciences FY2025 revenue up 4% to $344M, net loss of $24.2M vs income of $18.2M in 2024

## Summary
- FY2025 revenue $344.2M (+4% YoY); excluding discontinued tests growth 34%. Core test reports (DecisionDx-Melanoma, TissueCypher) +37%.
- Q4 revenue $87.0M (+1%); core reports +42%. TissueCypher reports up 86% in FY2025.
- Net loss $24.2M ($0.83 loss per share) vs net income $18.2M ($0.66 EPS) in 2024. Adj. net loss per share $0.14.
- Adjusted EBITDA $44.0M (FY2025) vs $75.0M (2024); net cash from ops $64.3M; cash & securities $299.5M at year-end.
- 2026 revenue guidance $340-350M; AdvanceAD-Tx limited launch; multiple publications support test utility.

## SEC filing metadata
- accession: 0001628280-26-012263
- form_type: 8-K
- ticker: CSTL
- cik: 0001447362
- company_name: CASTLE BIOSCIENCES INC
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447362/000162828026012263/0001628280-26-012263-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447362/000162828026012263/cstl-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-012263
- JSON: https://secwatch.observer/filing/0001628280-26-012263.json
- Plain text: https://secwatch.observer/filing/0001628280-26-012263.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.